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Abstract The aminoalkylindole BML-190 and diarylpyrazole
AM251 ligands have previously been shown to bind to cannabi-
noid CB2 and CB1 receptors, respectively. In HEK-293 cells
stably expressing the human CB2 receptor, BML-190 and
AM251 potentiated the forskolin-stimulated accumulation of
cAMP. Moreover, the CB2 receptor can interact productively
with 16z44, a promiscuous GK16=z chimera. BML-190 and
AM251 reduce the basal levels of inositol phosphate production
in cells expressing the CB2 receptor and 16z44. These results
demonstrate that BML-190 and AM251 act as inverse agonists
at the human CB2 receptor acting via GKi=o and GKq family-
coupled pathways.
1 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The pharmacological targets of psychoactive cannabinoids
and endogenous eicosanoids are the cannabinoid receptors.
Two cannabinoid receptor subtypes have been identi¢ed and
are termed CB1 and CB2 (for a review see [1]). The two sub-
types share approximately 48% homology and utilize Gi=o
heterotrimeric G proteins to inhibit the activity of adenylyl
cyclase and stimulate mitogen-activated protein kinases. CB1
receptors also regulate the activity of potassium and calcium
channels [2]. CB1 receptors are widely distributed in the cen-
tral and peripheral nervous system as well as in peripheral
tissues. In contrast, CB2 receptors are primarily expressed in
immune cells and in numerous other tissues including the
spleen, pancreas, thymus and tonsils [1].
Cannabinoids have been implicated in many physiological
processes including the control of pain perception, motor
function, memory, suppression of humoral immune responses,
stimulation of lymphocyte proliferation as well as providing
relief from the symptoms of multiple sclerosis and the side
e¡ects of chemotherapy [1]. Furthermore, cannabinoid ago-
nists modulate cytokine expression and promote tumor
growth [3]. CB2 receptor agonists have also been demon-
strated to induce apoptosis in tumors of immune origin
[4]. This wide spectrum of e¡ects has led to an intensive search
for ligands that are able to selectively modulate the binding
of endogenous cannabinoids at each receptor subtype and
regulate their corresponding intracellular signalling path-
ways.
The library of ligands that are selective for either CB1 or
CB2 receptors is growing rapidly [5]. Often the data accom-
panying the descriptions of the ligands’ synthesis only detail
the receptor subtype selectivity. One such ligand is indome-
thacin morpholinylamide, also known as BML-190 [6]. BML-
190 was reported as having a Ki value for CB2 receptors of
435 nM with 50-fold selectivity over CB1 receptors. A subse-
quent report used BML-190 as an agonist in a study of the
e¡ect of cannabinoids on the proliferation of cancer cells [7].
However, no supporting data were provided to demonstrate
the agonism of BML-190. AM251 (N-(piperidin-1-yl)-5-(4-io-
dophenyl)-1-(2,3-dichlorophenyl)-4-methyl-1H-pyrazole-3-car-
boxamide) was produced as a derivative of the CB1 receptor
antagonist/inverse agonist SR141716A [8]. As AM251 has a
high a⁄nity for CB1 receptors it has come to be widely used
as a CB1-selective antagonist in numerous pharmacological
and functional studies [9,10] even though its e⁄cacy at CB2
receptors has not been clearly established.
With the increasing recognition that inverse agonists are
useful therapeutic tools in the management of pathophysio-
logical states [11^13] it is particularly important to distinguish
between antagonists and inverse agonists in order that the
e¡ects of di¡erent classes of ligand can be thoroughly eval-
uated. The purpose of the present study was to establish the
e¡ect of BML-190 and AM251 on the Gi=o-mediated inhibi-
tion of cAMP accumulation in a human embryonic kidney
293 (HEK-293) cell line stably expressing the human CB2
receptor (293/CB2). In addition, following demonstration
that the CB2 receptor is able to functionally interact with a
chimeric GK16=z subunit, 16z44 [14], we showed that the pat-
tern of inositol phosphate (IP) production elicited by the
tested ligands mirrored their pattern of inhibition of cAMP
accumulation, and supports the notion that they act as inverse
agonists at the CB2 receptor.
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2. Materials and methods
2.1. Materials
The cDNA encoding the human CB2 receptor was provided by Dr.
David Shire (Sano¢ Recherche, Labe'ge, France). HEK-293 cells were
obtained from the American Type Culture Collection (ATCC CRL-
1573; Rockville, MD, USA). Ligands were purchased from Sigma-
RBI (St. Louis, MO, USA) and Tocris Cookson (Bristol, UK).
[3H]Adenine and myo-[3H]inositol were purchased from Amersham
Biosciences (Bucks, UK). Cell culture reagents, Lipofectamine1 and
Plus1 reagent were from Invitrogen Life Technologies (Carlsbad, CA,
USA). Scintillation £uid was from EGpG Wallac (Finland). All other
chemicals were purchased from Sigma Chemicals (St. Louis, MO,
USA).
2.2. Generation of stable cell lines
HEK-293 cells were seeded into 25 cm2 culture £asks at a density of
3U105 cells per £ask. The following day, 2 h before transfection, fresh
minimal essential medium (MEM) with 10% (v/v) fetal bovine serum
(FBS), 50 U/ml penicillin and 50 Wg/ml streptomycin was added to the
cells. 10 Wg of receptor cDNA was introduced into the cells using the
calcium phosphate precipitation method [15]. Transfected cells were
cultured for 16 h at 37‡C in a water-saturated atmosphere of 95% air
and 5% CO2. Cells were washed with phosphate-bu¡ered saline and
cultured in normal growth medium for a further 24 h before selection
by the addition of 400 Wg/ml G418. Following the death of all mock-
transfected cells grown in the same selection medium, transfected cells
were re-plated at a low density and individual colonies were isolated
and maintained in growth medium containing 150 Wg/ml G418.
2.3. cAMP and IP accumulation assays
293/CB2 cells were labeled with [3H]adenine (1 WCi/ml) in MEM
with 1% FBS for 20^24 h. Labelled cells were challenged with 50 WM
forskolin and appropriate drugs for 30 min at 37‡C and assayed for
cAMP accumulation as described previously [16]. For IP assays,
2U105 293/CB2 cells were transiently transfected with 16z44 and/or
pcDNA3 using Lipofectamine1 and Plus1 reagents according to the
manufacturer’s instructions. Cells were labelled, challenged with drugs
and assayed for IP production as previously described [14]. Triplicates
were performed for each data point and at least three separate trials
were done for each ligand. Data were analyzed by non-linear least-
squares regression using the computer-¢tting program Prism 3.02
(GraphPad Software, San Diego, CA, USA).
3. Results
We generated a HEK-293 cell line stably expressing the
human CB2 receptor (293/CB2). Following the selection pro-
cess using G418, resistant cells were replated at a low density
and 12 individual clones were isolated. To identify clonal cell
lines expressing the receptor, intracellular cAMP accumula-
tion was determined following challenge with the ligands
JWH 015 ((2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-
methanone) and BML-190. In each of the 12 clonal cell lines,
JWH 015 elicited a reduction in the forskolin-stimulated
cAMP accumulation, however cAMP levels were potentiated
when challenged with 10 WM BML-190. This e¡ect was not
observed in wild-type HEK-293 cells. The level of forskolin-
stimulated cAMP accumulation varied between clones, as did
the degree of potentiation by BML-190. BML-190 stimulation
of several of the clones increased forskolin-stimulated cAMP
accumulation approximately two-fold. One of these clones
was chosen for further investigation.
To characterize the response of 293/CB2 cells to JWH 015,
BML-190 and other cannabinoid ligands, a series of dose^
response curves were constructed (Fig. 1). Agonists JWH
015 and WIN 55,212-2 (R(+)-[2,3-dihydro-5-methyl-3-(4-mor-
pholinylmethyl)pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naph-
thalenylmethanone mesylate) caused reductions of 44S 7.5%
and 37S 5% in the forskolin-stimulated accumulation of
cAMP with EC50 values of 4.5 S 4.2 nM and 1.2S 0.5 nM
(n=3), respectively. BML-190 caused an increase in the for-
skolin-stimulated cAMP levels of 103S 17% with an EC50
value of 980S 70 nM (n=3). To compare the properties of
BML-190 with a known cannabinoid inverse agonist, dose^
response curves were constructed using 6-iodopravadoline
(AM630). This ligand increased the level of cAMP accumu-
lation by 127S 7% with an EC50 value of 90.3S 19.6 nM
(n=3). AM251 also behaved as an inverse agonist in our
system, potentiating the forskolin response by 99S 7.5%
with an EC50 value of 650S 30 nM (n=3). The CB1-selective
agonist, ACEA, at a concentration of 10 WM had no e¡ect on
the cAMP accumulation in 293/CB2 cells (data not shown).
To further con¢rm the characteristics of these ligands we
tested their ability to activate intracellular IP production via
Gq=11 family member K-subunits. None of the ¢ve ligands
were able to alter basal IP levels in 293/CB2 cells, suggesting
that the CB2 receptor is unable to couple to endogenously
expressed GKq=11 subunits (data not shown). Similarly, no
response was observed in 293/CB2 cells transiently transfected
with the GK16 subunit. However, 293/CB2 cells transiently
transfected with the cDNA encoding a promiscuous GK16=z
chimera, 16z44 (0.5 Wg DNA/well) [14], showed increased lev-
els of IP accumulation in the absence of CB2 ligands (approx-
imately 17-fold higher than basal responses in the same cell
line transfected with pcDNA3). Following challenge with 10
WM WIN 55,212-2 or JWH 015, the IP levels increased by
28S 4% and 43S 13% (n=3), respectively. In contrast, 10
WM of BML-190, AM630 and AM251 decreased IP accumu-
lation by 38S 9%, 62S 9% and 73S 4% (n=3), respectively.
These ligands had no e¡ect on the basal IP levels in 293/CB2
cells transfected with pcDNA3 (data not shown).
Given the high degree of basal activity in 293/CB2 cells
transiently expressing 16z44, the e¡ect of cDNA amounts
used in transfections was examined for subsequent basal ac-
tivity as well as cell responsiveness to the agonist JWH-015
and inverse agonist AM251 (Fig. 2). As the amount of cDNA
increased from 62.5 ng/well to 1 Wg/well, the basal activity
increased approximately 12-fold. At cDNA concentrations
of 0.25^0.5 Wg/well an increase in the basal level IP accumu-
Fig. 1. E¡ects of cannabinoid receptor ligands on the forskolin-in-
duced cAMP accumulation in 293/CB2 cells. 293/CB2 cells were la-
beled with 1 WCi/ml [3H]adenine for 20^24 h before the assay.
cAMP accumulation was assayed following 50 WM forskolin and
drug treatments as indicated for 30 min. Data points are
meanSS.D. values of triplicate determinations in a single experi-
ment.
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lation was measured upon challenge with 10 WM JWH 015.
However, it is clear that at the highest concentration of cDNA
tested the agonist was unable to promote any further increase
in IP accumulation over basal levels (Fig. 2). In contrast,
AM251 was able to reduce the IP accumulation with increas-
ing e⁄cacy (approximately three-fold reduction of basal at
0.125 Wg/well of DNA to four-fold reduction at 1 Wg/well)
as the amount of cDNA rose (Fig. 2). Dose^response curves
were constructed for JWH 015, AM251 and BML-190 to de-
termine the potencies of these ligands acting through the
16z44-coupled pathway. The EC50 values were determined
to be 10.3S 1.2 nM, 261S 37 nM and 494S 207 nM (n=3),
respectively (Fig. 3).
4. Discussion
Our results show that both BML-190 and AM251 behave
as inverse agonists at the human cannabinoid CB2 receptor.
This was demonstrated by their ability to dose-dependently
increase the forskolin-stimulated levels of cAMP in HEK-
293 cells stably expressing the receptor (Fig. 1). In the absence
of forskolin stimulation, BML-190 caused no change in
cAMP levels (data not shown), suggesting that this e¡ect oc-
curs because of the ability of BML-190 to stabilize a form of
the receptor that does not freely activate Gi=o proteins, rather
than by a direct activation of Gs proteins. We con¢rmed the
functionality of our heterologous expression system by dem-
onstrating that the non-selective agonist, WIN 55,212-2 [5],
and the CB2 receptor selective agonist, JWH 015 [17], both
inhibited forskolin-stimulated cAMP accumulation. The po-
tencies and e⁄cacies that we observed for WIN 55,212-2 are
in agreement with previously published values for heterolo-
gously expressed human CB2 receptors [18,19]. Furthermore,
as has been previously reported for preparations of CB2 re-
ceptors, WIN 55,212-2 was a more potent agonist than JWH
015 [20].
The inverse agonist AM630 has previously been shown to
enhance forskolin-stimulated cAMP production in CB2-trans-
fected cells (EC50 = 230 nM) and to inhibit [35S]GTPQS bind-
ing to CB2 receptor membranes (EC50 = 76.6 nM) [21]. Our
data con¢rm the inverse agonist activity of this ligand at CB2
receptors and demonstrate that AM630 acts with approxi-
mately 10-fold higher potency and approximately 1.3-fold
greater e⁄cacy than BML-190. Similarly, AM251, which has
previously been classi¢ed as a CB1 receptor antagonist [1],
acted as a CB2 receptor inverse agonist in our system. The
potencies and e⁄cacies were of a similar magnitude as those
of BML-190. This suggests that results obtained using AM251
to pharmacologically de¢ne receptor subtypes and responses
should be con¢rmed with other ligands.
In order to con¢rm the inverse agonist activity of BML-190
and AM251 in a second system, we have shown that the
human CB2 receptor is able to functionally interact with the
16z44 chimera. This mutant harbors 44 GKz-speci¢c sequences
at the C-termini of GK16 and is more promiscuous in its
ability to couple to Gi=o- and Gs-linked receptors [14]. Our
experiments also determined that the human CB2 receptor is
unable to activate phospholipase CL (PLC) via endogenous
Gq=11 or GK16 proteins. This con¢rms previous observations
that the human CB2 receptor does not functionally couple to
members of the GKq subfamily [22].
When transiently expressed in 293/CB2 cells the basal IP
levels increased with increasing amounts of 16z44 used. At a
concentration of 62.5 ng/well of 16z44 cDNA, the level of
receptor/G protein coupling was inadequate to reproducibly
observe signi¢cant modulation by cannabinoid ligands (Fig.
2). At 0.125 Wg/well of 16z44 cDNA, a higher basal level of IP
accumulation was observed. JWH 015 was unable to further
stimulate IP accumulation but AM251 did signi¢cantly inhibit
basal levels (Fig. 2). We propose that at a limiting concentra-
tion of 16z44, this K-subunit preferentially interacted with an
active form of the CB2 receptor rather than the inactive form,
accounting for the increased basal activity. However, addition
of agonist produced no further increase in signalling via
16z44, as all available K-subunits were already coupled to
active receptors. Under these conditions the inverse agonist,
Fig. 2. E¡ects of cannabinoid receptor ligands on IP levels in 293/
CB2 cells transiently transfected with varying amounts of 16z44.
293/CB2 cells were transiently transfected with 1 Wg of total cDNA
(varying amounts of 16z44 and balanced with pcDNA3). The fol-
lowing day cells were labelled with myo-[3H]inositol. Forty-eight
hours following transfection, cells were challenged with 10 WM li-
gands and assayed for IP accumulation. IP accumulation is pre-
sented as the ratio of [3H]IPs to total cellular [3H]inositol-containing
compounds multiplied by 1000. Data points are meanSS.D. values
of triplicate determinations in a single experiment. *Signi¢cantly dif-
ferent from the basal level; P6 0.05 by unpaired Student’s t-test.
Fig. 3. Dose-dependent ligand stimulation of IP levels in 293/CB2
cells transiently transfected with 16z44. 293/CB2 cells were transi-
ently transfected with 0.25 Wg/well (JWH-015) or 0.5 Wg/well
(AM251 and BML-190) 16z44 cDNA. Transfected cells were la-
belled and assayed for IP formation in the presence of increasing
concentrations of the indicated ligands. Data points are meanSS.D.
values of triplicate determinations in a single experiment. Basal IP
levels are normalized to 100%.
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AM251, was still able to stabilize the inactive, uncoupled form
of the receptor and thus, a reduction of basal activity was
measured. As the amounts of cDNA were increased to 0.25
Wg/well and above, the basal activity increased and we were
able to further stimulate IP accumulation with JWH 015 and
inhibit basal activity with AM251. This suggests that as the
16z44 concentration increased this K-subunit was bound to
both active and inactive forms of the receptor to allow mea-
surement of the activities of both agonists and inverse ago-
nists. At the highest level of DNA tested (1 Wg/well) the basal
activity was so high that further IP stimulation by JWH 015
was not observed. A functional coupling between CB2 and
16z44 was still in operation as AM251 was able to reduce
the basal activity (Fig. 2). Dose^response curves established
that JWH 015, BML-190 and AM251 activated or inhibited
IP accumulation through 16z44 in a dose-dependent manner
(Fig. 3). The EC50 values for these three ligands are of the
same order of magnitude whether signalling through Gi=o or
16z44.
These data not only con¢rm the inverse agonistic activity of
ligands BML-190 and AM251 in a second independent assay
system but also establish for the ¢rst time that the human CB2
receptor is able to signal via a GK16=z chimera to modulate
PLC-coupled intracellular signalling pathways. This will now
facilitate the incorporation of the CB2 receptor into high-
throughput screening assays by allowing it to be assayed
alongside other G protein-coupled receptors in assay plat-
forms that detect changes in the PLC-coupled signalling path-
ways [23]. The basal activity observed in cells expressing both
the CB2 receptor and 16z44 will allow assays to be established
that are capable of detecting agonists and inverse agonists.
Such ligands will have applications in the management and
treatment of many clinical conditions. Of particular interest
are the recent observations that the in vivo administration of
a CB2-selective antagonist reduced the promotion of tumor
growth in mice treated with a cannabinoid [3]. It has also
been demonstrated that the ¢rst CB2 receptor inverse agonist
produced, SR144528 [24], and the inverse agonist JTE-907
have anti-in£ammatory e¡ects in a mouse model when ad-
ministered orally [25]. The isolation and characterization of
speci¢c, potent and e⁄cacious inverse agonists of the CB2
receptor will contribute towards the development of the
management of tumor growth and in£ammation by manipu-
lation of cannabinoid receptor signalling activity.
In conclusion, our results demonstrate that both BML-190
and AM251 have negative intrinsic activity at the human CB2
receptor stably expressed in HEK-293 cells. These observa-
tions will allow both ligands to be used with more precision
in the pharmacological characterization of cannabinoid recep-
tors and the analysis of the intracellular and physiological
responses that they induce. Finally, our ¢nding that the hu-
man CB2 receptor is able to signal via 16z44-coupled path-
ways will contribute to the search for new CB2 receptor li-
gands.
Acknowledgements: This work was supported in part by grants from
the Research Grants Council of Hong Kong (N_HKUST 602/00), the
University Grants Committee (AoE/B-15/01), the Innovation and
Technology Commission of Hong Kong (AF166/99), and the Hong
Kong Jockey Club. Y.H.W. is a recipient of the Croucher Senior
Research Fellowship.
References
[1] Howlett, A.C., Barth, F., Bonner, T.I., Cabral, G., Casellas, P.,
Devane, W.A., Felder, C.C., Herkenham, M., Mackie, K., Mar-
tin, B.R., Mechoulam, R. and Pertwee, R.G. (2002) Pharmacol.
Rev. 54, 161^202.
[2] Pertwee, R.G. (1997) Pharmacol. Ther. 74, 129^180.
[3] Yuan, M., Kiertscher, S.M., Cheng, Q., Zoumalan, R., Tashkin,
D.P. and Roth, M.D. (2000) J. Neuroimmunol. 133, 124^131.
[4] McKallip, R.J., Lombard, C., Fisher, M., Martin, B.R., Ryu, S.,
Grant, S., Nagarkatti, P.S. and Nagarkatti, M. (2002) Blood 100,
627^634.
[5] Pertwee, R.G. (1999) Curr. Med. Chem. 6, 635^664.
[6] Gallant, M., Dufresne, C., Gareau, Y., Guay, D., Leblanc, Y.,
Prasit, P., Rochette, C., Sawyer, N., Slipetz, D., Tremblay, N.,
Metters, K. and Labelle, M. (1996) Bioorg. Med. Chem. Lett. 6,
2263^2268.
[7] Melck, D., De Petrocellis, L., Orlando, P., Bisogno, T., Laezza,
C., Bifulco, M. and Di Marzo, V. (2000) Endocrinology 141,
118^126.
[8] Lan, R., Liu, Q., Fan, P., Lin, S., Fernando, S.R., McCallion,
D., Pertwee, R. and Makriyannis, A.J. (1999) J. Med. Chem. 42,
769^776.
[9] Gardner, B., Zu, L.X., Sharma, S., Liu, Q., Makriyannis, A.,
Tashkin, D.P. and Dubinett, S.M. (2002) Biochem. Biophys.
Res. Commun. 290, 91^96.
[10] Trettel, J. and Levine, E.S. (2002) J. Neurophysiol. 88, 534^539.
[11] Morisset, S., Rouleau, A., Ligneau, X., Gbahou, F., Tardivel-
Lacombe, J., Stark, H., Schunack, W., Ganellin, C.R., Schwartz,
J.C. and Arrang, J.M. (2000) Nature 408, 860^864.
[12] Strange, P.G. (2001) Pharmacol. Rev. 53, 119^133.
[13] Weiner, D.M., Burstein, E.S., Nash, N., Croston, G.E., Currier,
E.A., Vanover, K.E., Harvey, S.C., Donohue, E., Hansen, H.C.,
Andersson, C.M., Spalding, T.A., Gibson, D.F., Krebs-Thom-
son, K., Powell, S.B., Geyer, M.A., Hacksell, U. and Brann,
M.R. (2001) J. Pharmacol. Exp. Ther. 299, 268^276.
[14] Mody, S.M., Ho, M.K., Joshi, S.A. and Wong, Y.H. (2000) Mol.
Pharmacol. 57, 13^23.
[15] Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular
Cloning: A Laboratory Manual, Cold Spring Harbor Laborato-
ry Press, Cold Spring Harbor, NY.
[16] Wong, Y.H. (1994) Methods Enzymol. 238, 81^94.
[17] Gri⁄n, G., Fernando, S.R., Ross, R.A., McKay, N.G., Ashford,
M.L., Shire, D., Hu¡man, J.W., Yu, S., Lainton, J.A. and Pert-
wee, R.G. (1997) Eur. J. Pharmacol. 339, 53^61.
[18] Slipetz, D.M., O’Neill, G.P., Favreau, L., Dufresne, C., Gallant,
M., Gareau, Y., Guay, D., Labelle, M. and Metters, K.M. (1995)
Mol. Pharmacol. 48, 352^361.
[19] Tao, Q. and Abood, M.E. (1998) J. Pharmacol. Exp. Ther. 285,
651^658.
[20] Martin, R.S., Luong, L.A., Welsh, N.J., Eglen, R.M., Martin,
G.R. and MacLennan, S.J. (2000) Br. J. Pharmacol. 129, 1707^
1715.
[21] Ross, R.A., Brockie, H.C., Stevenson, L.A., Murphy, V.L., Tem-
pleton, F., Makriyannis, A. and Pertwee, R.G. (1999) Br.
J. Pharmacol. 126, 665^672.
[22] Ho, B.Y., Uezono, Y., Takada, S., Takase, I. and Izumi, F.
(1999) Receptors Channels 6, 363^374.
[23] Milligan, G., Marshall, F. and Rees, S. (1996) Trends Pharmacol.
Sci. 17, 235^237.
[24] Portier, M., Rinaldi-Carmona, M., Pecceu, F., Combes, T., Poi-
not-Chazel, C., Calandra, B., Barth, F., Le Fur, G. and Casellas,
P. (1999) J. Pharmacol. Exp. Ther. 288, 582^589.
[25] Iwamura, H., Suzuki, H., Ueda, Y., Kaya, T. and Inaba, T.
(2001) J. Pharmacol. Exp. Ther. 296, 420^425.
FEBS 26963 29-1-03
D.C. New, Y.H. Wong/FEBS Letters 536 (2003) 157^160160
